Articles

Videos

Podcasts

Clinical Role

Phase 2 clinical trial results assessing sotorasib in previously treated patients with NSCLC showed that the drug presented a median OS of 12.5 months among 124 patients.

Trial Results Show Sotorasib Is First, Only KRAS G12C Inhibitor With Overall Survival Data for Non-small Cell Lung Cancer

The findings led to the FDA accepting the supplemental Biologics License Application and Priority Review designation for treatment, according to a Gilead press release.

Brexucabtagene Autoleucel Demonstrates High Response Rate with Relapsed, Refractory B-cell Acute Lymphoblastic Leukemia

Home infusion within the larger ambulatory infusion setting poses specific advantages and disadvantages in relation to other available location options.

Home-Based Intravenous Cancer Therapies: The Benefits and Disadvantages

A patient with multiple providers and health problems seeks a pharmacist’s knowledge for managing her prescribed and OTC drug products.

Brown Bag Consult®: Breast Cancer and Additional Stressors

Avapritinib is approved for adult patients with advanced systemic mastocytosis, including individuals with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

Updated research offers an additional 2 years of follow-up data and statistics on treatment with a combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.

Study: Combination Targeted Therapy Provides Durable Remission for Patients with Chronic Lymphocytic Leukemia

Common factors that contributed to increased dissatisfaction at
work included workflow disruptions, role conflict, quantity of work,
organizational culture, and leadership support.

Survey: High Levels of Burnout are Prevalent Among Hematology/Oncology Pharmacists

The addition of daratumumab to lenalidomide and dexamethasone resulted in a significant benefit to overall survival in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression, according to the results of the phase 3 MAIA study.

Daratumumab Demonstrates Benefit to Overall Survival for Certain Patients with Multiple Myeloma

In the United States, endometrial cancer is the most common cancer of female reproductive organs.

What Pharmacists Should Know About Endometrial Cancer

The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.